Increasing Blood Oxygenation With D'OXYVA® Can Reduce the Effects of Underlying Health Issues on COVID-19 Infections

Share Article

A noninvasive transdermal delivery system, D'OXYVA®, could help reduce the impact of preexisting health conditions on the outcome of a COVID-19 infection.

News Image
“Based on this evidence, D'OXYVA®, the first biotech solution of its kind to improve overall oxygen-rich blood flow, is perfectly suited to help improve health outcomes of COVID-19 patients, whether or not they have preexisting conditions."

D'OXYVA® is a groundbreaking, completely painless, and noninvasive transdermal delivery system shown to improve blood perfusion and tissue oxygenation. A proprietary product of Circularity Healthcare, a private company focused on manufacturing medical technological products, D'OXYVA® could help reduce the impact of preexisting health conditions on the outcome of a COVID-19 infection.

People with an increased risk for COVID-19 infection are mainly those with previous health problems, such as cardiovascular disease, diabetes, respiratory disease, old age, and/or immunodeficiency. Among those risk factors, cardiovascular disease stands as one of the most dangerous. Even though the full extent of the interplay between cardiovascular disease and COVID-19 is not yet known, a recently discovered effect of a COVID-19 infection is the development of potentially deadly blood clots. By increasing tissue oxygenation through improved oxygen-rich blood flow, the health risk associated with preexisting cardiovascular disease can be countered by diminishing the effects of blood clotting and reducing the physical heart exertion needed to pump blood to major organs.

So far, acute treatment of serious cases of COVID-19 has involved using blood thinners (anticoagulants), like heparin, and oxygenation. D’OXYVA® represents a new treatment option.

D'OXYVA® uses vaporized, ultra-purified carbon dioxide to improve the body’s self-healing functions. It delivers this non-toxic compound via a non-invasive skin-delivery method, which has been shown to be more effective and safer than inhalation, a routine delivery method in hospital settings. The FDA-approved medical CO2 gets mixed with water inside the device, producing an active solution of supersaturated CO2 and water (H2O) vapor that improves skin microcirculation and blood circulation after dissolving into the skin.

Clinical studies have shown that D'OXYVA® increases O₂ saturation in patients treated with transdermal CO₂, in comparison to controls up to two hours after application; lowers heart rate; and increases perfusion index.

Based on this evidence, D'OXYVA®, the first biotech solution of its kind to improve overall oxygen-rich blood flow, is perfectly suited to help improve health outcomes of COVID-19 patients, whether or not they have preexisting conditions.

ABOUT CIRCULARITY HEALTHCARE
Circularity Healthcare, LLC, headquartered in Pasadena, California, is an emerging world leader in proprietary circulatory health and noninvasive delivery technologies, committed to helping improve life quality by developing, manufacturing, and marketing medical, pharmaceutical, and consumer health products. Circularity specializes in groundbreaking noninvasive technologies for affordable and portable transdermal delivery systems, and is pursuing regulatory approval worldwide as a way of handling cardiovascular and microcirculatory blood flow issues, as well as immune and autonomic nervous system disorders.

For more information, please visit http://www.circularityhealthcare.com or http://www.doxyva.com. Medical experts (Rx only) can visit http://www.doxyvaforwound.com to send general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info@doxyva.com info@circularityhealthcare.com or by phone toll free at 1-855-5DOXYVA or at 1-626-244-8090.

Forward-Looking Information
This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Melissa Edwards
Visit website